Copy
View this email in your browser
June 19, 2022
Editorial: 
Happy Father’s Day, Vitamins take the lead

This is the first year I have hesitated to announce HAPPY FATHER’s Day to the  Father’s with sons and daughters they love, play, and care for. 
I hope you have a GREAT DAY celebrating the joy of being a dad! 
I still recall the incredible love that embraced me the moment my daughter was born, a love like no other! No words could ever express this feeling! 
 
Yet, in May 2022, the BC Government, may not agree with you being a Father, as they made the following announcement, which seems to indicate Father and even Son are words which in future will be phased out of the English language, and even perhaps criminalized.

‘Approximately 90% of the amendments address binary language such as “he,” “she,” “himself” or “herself,” and the remaining 10% amend gender-specific terms like “aunt,” “father” or “son.” Thirty-three regulations will also be updated through amendments unrelated to gendered language. For example, removing the outdated term “substance abuse” and replacing it with “substance use.”’
https://news.gov.bc.ca/releases/2022JERI0012-000450
 
I assume religions that use the term, Father, Son, and Holy Ghost may now be left with only the Holy Ghost to guide them on their way back home to heaven.
 
Vitamins take the lead
 
Prior to covid, which has yet to be isolated to prove it exists, vitamin sales were slightly dropping [3.8%] however since covid, which does not exist, sales of vitamins have increased 22%! [see report below in FRN]. 
 
There is no question the supplement industry benefits from ‘sickness’ and ‘dis-ease’ as people seek out safer more effective ways to treat illness than pharmaceutical drugs with their inherent side effects.
 
Did you know in the past 38 years there have been no deaths associated with vitamin use? 
Did you know most vitamins are produced by pharmaceutical  manufacturers using chemical solvents to extract the vitamin from the plant source whether corn, soy, or other? 
Did you know most of the vitamins are produced in China, thank you, China!
When I was in retail, we would recommend with confidence, high dose vitamin programs for a variety of health conditions, with noticeable results!!
Are you aware of the Orthomolecular Foundation, http://orthomolecular.org/, and the research done by Pauling, Hoffer, Whitaker, Sinatra, Rapp, Wright, Schuss, and many others on cancer, heart, schizophrenia, brain, ADHD, suicide, common colds, immune, and many other diseases?
How much time do you spend educating on megavitamin therapy?
 
I think vitamins should be the first choice of medicine, or at least be included with medical treatments, to help with the healing and recovery process. 
 
Even better is using vitamins as preventative medicine, to keep you well.
 
Happy Sales,
dp
Lead Stories

 
Jennifer Kerr integrated naturopathic and conventional medicine to lessen the burden of the health care system
https://seewhatgrows.org/jennifer-kerr-integrate-naturopathic-and-conventional-medicine-to-lessen-burden-of-the-health-care-system/
 
Jennifer Kerr is the Foundation’s latest post secondary bursary recipient in naturopathic medicine. Her full video interview is on the Foundation’s YouTube channel here: https://www.youtube.com/watch?v=Sle6TYeATCQ\



The Analyst’s Take: Vitamins dominate market, reaching $18.70 billion 

The overall vitamin category was considered sleepy before the pandemic, with growth dropping to 3.8% in 2019, the lowest growth rate in five years. 2020 was a game changer for growth in the category given immune and general health demands, spiking to a more-than-impressive 22.3%.
 
The future is frictionless at Nourish + Bloom Market
Education:
Reduce your customers risk and increase your sales

“If only our customers would buy more from us” is a resounding phrase that is heard throughout many businesses these days as the demand for increased sales to offset rising costs. While we may wish to have more revenue by selling more, our

customers are at the other end of the spectrum facing rising costs themselves. They are looking at their money

and wondering how they can make it last longer. Every time they spend their money, they are facing a risk. Yet more often than not as businesses and organizations we don’t consider the risks that our customers face on a daily basis when thinking about buying from us.

Read More
Mosquitos & Malaria
From the Natural Path Newsletter
by Linda Woolven M.H., R.Ac & Ted Snider
 
Natural citronella has gone mainstream: you can find citronella mosquito repellents everywhere. But the best natural insect repellent may be yarrow extract (Phytomed 1998;5(4):311-23). The same study that ranked yarrow number one also found citronella and eucalyptus oils to be effective and lemongrass to be 85% effective as a mosquito repellent. A study of over 4,000 natural compounds found lemongrass to be the very best (Greenhouse Management and Production 1999). A third study also found lemongrass to be extremely effective (Acta Trop 2015;142:127-30). This study also found the essential oil ylang ylang to work very well. The essential oils were put in a carrier of coconut oil, soybean oil or olive oil. 

A study that looked at the Aedes aegypti mosquito that carries dengue fever found citronella and cinnamon essential oils to be effective. The most effective essential oil against this strain of mosquito was the little known litsea essential oil (J Athropod Borne Dis 2016;10(3):370-380). 

While the Aedes aegypti mosquito carries dengue fever, it is Anopheles stephensi that carries malaria. When a study looked at these 2 mosquitoes as well as the Culex quinquefasciatus, whose bite can cause encephalitis, the most effective essential oils included litsea again as well as cajeput, violet and catnip (Parasitology Research 2006;99:478). 

A study that put essential oils on people’s forearms under laboratory conditions found that undiluted clove essential oil provided 100% repellency against 3 species of mosquito for 2-4 hours (Phytother Res 2005;19(4):303-9), which is a very impressive result. 

Another study suggests that the essential oils of turmeric and citronella are effective (J Vector Ecol 2001;26(1):76-82). One study actually suggests that the essential oil and extract of turmeric may be comparable to DEET (J Med Entomol2015;52(5):979-86).

A recent laboratory study suggests that fatty acids from coconut oil is a stronger and longer lasting repellant than DEET and that it works against mosquitoes and ticks (Sci Rep. 2018 Sep 19 ;8(1):14053). 

Carrot seed essential oil may also be effective (J Am Mosq Control Assoc. 2018 12;34(4):272-280). And one study found that celery extract is remarkably effective when applied to the skin  (Trop Med Int Health. 2005 Nov;10(11):1190-8) Neem oil may also be effective (J Insect Sci. 2019 Nov 1;19(6)).

Maleria
For protection from malaria, you should know about a species of the herb wormwood called Artemisia annua, or Sweet Annie. 

Malaria is caused by Plasmodium, a single cell parasite transmitted by mosquitoes. It can be deadly. According to the World Health Organization, in 2017, there were an incredible 219 million cases around the world. 

Artemisia annua is a traditional herbal treatment for malaria in Asia. In 2015, Tu Youyou won the Nobel Prize in Medicine for her work in 1972 in isolating artemisinin as one of the antimalarial components of Artemisia annua and developing it into a drug that saved the lives of millions of people. The problem was that the Plasmodium parasite began to develop resistance to the drug. The solution was to begin combining artemisinin with other antimalarial drugs into a cocktail known as Artemisinin Combination Therapies (ACTs). But, in time, the clever little parasite began to adapt and develop resistance to that pharmaceutical treatment as well. The need became urgent for treatments that were more resilient to resistance. 

Artemisia annua has a 2,000 year history of use that is backed up by research in China and at the Walter Reed Army Research Institute in the US. Though artemisinin got all the attention, Artemisia annua actually has more than 20 antimalarial components that work synergistically against the malaria parasite, making it a promising challenger to the drug. The herb has demonstrated a greater than 95% malaria cure rate in small studies with the important advantage that drug resistance was 3 times greater with the artemisinin drug. 
A controlled unblinded study found that Artemisia annua tea was as effective at symptom relief as quinine and effective, but not as effective, at completely curing the malaria (Trans R Soc Trop Med Hyg 2004;98:318-321). 

Now, Sweet Annie has been put to its most important test. A double-blind study compared Artemisia annua to an African species of wormwood known, very imaginatively, as African wormwood (Artemisia afra), and to ACT. The study included 943 children and adults with malaria. The study did not include people whose malaria was already severe. Each person was given either ACT or .33 litres of tea made from one of the two wormwoods every 8 hours for 7 days. The tea was made from 5g of dried leaves and twigs that were steeped in boiling water for 10 minutes. 

After one day, the parasite count went down by 85.2% in the ACT group but by 97.7% in both of the artemisia groups. In both artemisia groups, by day 2, there was a total clearance of the parasite; some people in the ACT group still had parasites until day 14. By the second day, the malaria cure rate was 34.3% on the ACT but it was 88.8% in the African wormwood group and 96.4% in the Sweet Annie group. 

By day 28, the cure rate for children was 49.5% on ACT, 91.2% on African wormwood and 100% on Sweet Annie. For adults, the cure rate was 30% on ACT, 90.7% on African wormwood and, again, a full 100% on Sweet Annie. In both wormwood groups, fever cleared in 24 hours versus 48 hours on ACT. 

The two wormwoods were not only better, they were safer: 42.8% of ACT people experienced adverse events versus only 5% of the artemisia people. 

This study shows that both wormwoods and, perhaps especially Artemisia annua, or Sweet Annie, are better than and safer than ACT drug therapy. Given that the cure rate in the ACT group was so poor, it has been suggested that Artemisia annuamay be effective against ACT resistant malaria. 

Artemisia annua is safe, effective, inexpensive and easy to get (Phytomed 2019;57:49-56).
Goldenseal may also help, and a test tube study suggests that curcumin may inhibit the growth of malaria (Biochem Biophys Res Commun 2005;326(2):472-4). A double-blind, placebo-controlled study that combined zinc with high doses of vitamin A found that that combination significantly reduces the risk of malaria (Nutr J 2008;7:7). 

If you do get malaria, then, strangely, lime juice might help. A study of children with malaria found that adding lime juice to their treatment significantly sped up the time it took to reduce the load of parasites by more than 75% and significantly increased their odds of completely getting rid of the parasites by the third day of treatment (Phytother Res 2011;25(10):1547-50).

To Increase Your Sales by Educating Your Customers, Start Giving The Natural Path Newsletter to Your Customers Today! 

The Natural Path is a natural health newsletter specifically designed to help Canadian health food stores increase their sales by educating their customers. The Natural Path contains no advertising and never mentions a brand name.

Contact Ted Snider at tedsnider@bell.net or at 416.782.8211.

For comprehensive natural help with your health, make an appointment to see Linda Woolven now. Linda’s clinic is now open for virtual appointments. Linda is a master herbalist, acupuncturist, and solution-focused counselor with a practice in Toronto. Linda is also an artist whose paintings hang in galleries and private collections across North America. You can see some of her paintings here.
RT @GMOFreeUSA: Make sure your #oatmeal, oat flour, and oat milk are organic to reduce your exposure to #glyphosate and other toxic #pestic…

RT @5PriscillaKing: And why are genes "edited"? Traditional selective breeding makes bigger, hardier, or tastier crops. Gene splicing is us…

RT @careygillam: And another blow for @Bayer - as Solicitor General tells @USSupremeCourt that Monsanto petition for review of Hardeman Rou…

Artificial sweeteners - muscle wasting, cancer. heart disease, diabetes
 

COVID-19 is clearly no longer an emergency. The real emergency now is the continued use of the COVID “vaccines,” because they’re creating injuries on a level that is truly alarming and unprecedented. VAERS data reveal the COVID jabs have caused more harm in 18 months than all other vaccines on the market, combined, over the past three decades.
Read More
Health Crisis: The Ripple Effect from Environmental Toxins Within the Body

Neurotransmitters are chemicals in the brain that act as messengers between neurons. The effects of neurotransmitters are far-reaching and encompass most bodily processes, including: physical and cognitive performance, weight, the perception and response to pain, sleep patterns and our emotional and mental state of being. If neurotransmitter chemicals are imbalanced, the entire body is thrown off kilter, and it is estimated that 80 percent of people have some form of neurotransmitter imbalance.
 
A March 2010 study found that toxin exposure can affect neurotransmitters  ̶  even halt their activity. This leads us to wonder: how are we affected?
 
There is no doubt that human exposure to toxins is on the rise. According to WHO:
"Unintentional poisonings kill an estimated 355,000 people globally each year. In developing countries – where two thirds of these deaths occur – such poisonings are associated strongly with excessive exposure to, and inappropriate use of, toxic chemicals. In many such settings, toxic chemicals may be emitted directly into soil, air, and water – from industrial processes, pulp and paper plants, tanning operations, mining, and unsustainable forms of agriculture – at levels or rates well in excess of those tolerable to human health.”
 
One of the most notorious environmental toxins is Round-Up weed killer. In 2015, WHO declared Monsanto's signature product, Round-Up (or glyphosate), as carcinogenic. However, the tables seemed to turn in 2016 as Round-Up/glyphosate was given a clean bill of health by the UN’s joint meeting on pesticides residues (JMPR), just two days before a crunch EU vote on whether to relicense it. Interestingly, later in the year, it was announced that pharma giant Bayer would be purchasing Monsanto. Bayer CEO Werner Baumann said, "This step is entirely logical. The two companies are a perfect fit and complement each other ideally."
Read More
Leg Extensions Help Prevent Knee Pain and Degeneration
 
The Quadriceps muscle consists of 4 muscles on the front of your thigh that merge together above the kneecap to form the tendon (patellar tendon) that goes over the kneecap to insert on the lower leg bone (the Tibia). The Quadriceps muscle on the innermost aspect of the front of your thigh is known as the Vastus Medialis. Unlike the other Quadriceps muscles, it is not used during normal walking. It only contracts in the last 10 degrees of knee extension. As a result, many people have weak Vastus Medialis muscles from lack of use, which greatly contributes to the risk of knee problems, especially chondromalacia patella, patellofemoral syndrome, or lateral dislocation of the kneecap itself.

An excellent way to maintain Vastus Medialis strength is to incorporate the knee extension machine into your strength training program. Two to three sets of 8-12 repetitions, twice or three times a week, can make a big difference in preserving your knee function and preventing various knee inflammatory and degenerative conditions.

Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458583/

Dr. James Meschino
DC, MS, ROHP
Business News
The Road Ahead for CHFA: Town Hall Session | Wednesday, June 22, 2 PM ET (11 AM PT)

We’re approaching the halfway mark of 2022 (can you believe it?) and CHFA has a lot of new information to update our members on.
Please join President and CEO, Aaron Skelton, on Wednesday, June 22 at 2 p.m. ET (11 a.m. PT) for a virtual town hall where we’ll share what’s to come for CHFA. We’ll cover all things CHFA NOW, results from our member survey, and organizational updates regarding our advocacy efforts, including introducing our new partner, Huw Williams, President of Impact Public Affairs.
  • When: Wednesday, June 22 at 2 p.m. ET (11 a.m. PT)
  • Where: Join us from your couch, your office or even a dock at the cottage. This town hall is being broadcasted live via GoToWebinar.
  • Who: Presented by Aaron Skelton, President & CEO of CHFA and Huw Williams, President of Impact Public Affairs.

WhatIf Foods taps a secret ingredient for plant-based success
 
Mars partners with Perfect Day on animal-free chocolate
 
As milk prices soar, butter and cheese makers grapple over supply

Building resilient and sustainable supply chains in 2022 
 
When might the term 'alternative protein' be obsolete? 
 
How SuperMeat is helping cultivated meat take off
 
Online grocery sales bump up in May as inflation benefits mass retailers

Danone's venture arm invests in oat milk maker Minor Figures

InnovoPro partners on ice cream that harnesses the power of chickpeas

Specialty food sales swell to $175 billion

The Mysterious Food Processing Plant Fires & Livestock Deaths Conspiracy
Is there really a grand scheme being conducted by our societal overlords to cripple food supplies?
 
 

 
First made-in-Canada CAR-T cell therapy for cancer shows promise in clinical trial
 
OTTAWA, June 17, 2022 – More than a dozen people with cancer who had exhausted all treatment options are alive and cancer-free today thanks to a pioneering Canadian clinical trial of a highly personalized kind of immunotherapy. The results, presented at the 2022 Cell Therapy Transplant Canada Conference, could open the door to a new era of made-in-Canada immunotherapies for cancer.

Patients in the trial had their immune cells (T cells) removed and genetically engineered in a lab to enhance their cancer-killing ability. The supercharged immune cells, called CAR-T cells, were then infused back into the same patient.

While Health Canada has approved several commercial CAR-T therapies, access is restricted to people with just a few kinds of leukemia and lymphoma, and only if they fall into certain age ranges. Commercial CAR-T therapy is also very expensive and involves shipping cells to the United States and back.

The new trial, called Canadian-Led Immunotherapies in Cancer-01 (CLIC-01), is the first to manufacture CAR-T therapy in Canada. It uses a different kind of cell manufacturing that opens the door to less expensive and more equitable treatment.

“Canadian patients deserve access to the best cancer treatments in the world, and we need Canadian research to make this happen,” said Dr. Natasha Kekre, a scientist and hematologist at The Ottawa Hospital, associate professor at the University of Ottawa and principal investigator of CLIC-01. “We’re very excited about the preliminary results of this trial and we will be moving forward with new and exciting trials across Canada.”

Encouraging results are paving the way for more clinical trials

CLIC-01 launched in 2019 at The Ottawa Hospital and BC Cancer for patients with specific kinds of leukemia or lymphoma who had exhausted all other therapies and were given just months to live. Thirty patients have been treated so far, and 13 have had complete responses, meaning no more cancer cells can be detected in their blood. Two have partial responses and five have disease that is progressing, while nine patients have passed away from their cancer.

“Without this trial, I don’t think any of these patients would be alive today, so we are very encouraged by these results,” said Dr. Kekre. “So far, we are seeing an average progression-free survival of six months, which is very good in this patient population.”

CAR-T therapy is often associated with side effects such as cytokine release syndrome, and one patient on the CLIC trial passed away from this condition. Overall side effects among trial participants were lower than expected.

Canadian-Led Immunotherapies in Cancer (CLIC) program is expanding across the country

CLIC’s CAR-T therapy is manufactured jointly by The Ottawa Hospital’s Biotherapeutics Manufacturing Centre and BC Cancer’s Conconi Family Immunotherapy Lab. The trial was initially supported by BioCanRx, BC Cancer, BC Cancer Foundation, The Ottawa Hospital Foundation and the Ontario Institute for Cancer Research, with more recent contributions from the Ottawa Regional Cancer Foundation and the Leukemia and Lymphoma Society of Canada. The team is now working with partners in Toronto, Winnipeg and other cities to expand CAR-T infrastructure and enable more patients to have access to innovative CLIC trials.

“We are delighted to work with partners across Canada to build Canadian expertise, capacity for innovation and clinical trials in this field,” said Dr. Kekre. “We hope our work will lead to even better cell-based immunotherapies that work for more kinds of cancer, as well as innovative approaches for providing these therapies in the Canadian system.”

Young mother gets ‘a fighting chance’

For Camille Leahy, a 37-year-old single mother from Newmarket Ontario, CLIC-01 came just at the right time.

Camille was diagnosed with acute leukemia in January 2020. Despite many rounds of aggressive chemotherapy and a stem cell transplant, the cancer kept coming back and by March of 2021, she was out of options.

Fortunately, Camille’s cousin, who works at The Ottawa Hospital, had heard about the CLIC trial and suggested that Camille look into it. Camille was treated on September 15, 2021 and is now cancer-free.

“I feel better than I’ve felt in a very long time,” said Camille. “Being able to drive again and take my daughter to her softball games means the world to me. Even if the cancer comes back, this has given me precious time, and I know the research will help many others. It has given me a fighting chance.”

Patients who are interested in participating in clinical trials should speak with their cancer specialist.

About the Canadian-Led Immunotherapies in Cancer (CLIC) research program
The CLIC research program, established in 2016, brings researchers, clinicians and patients from across Canada together to build Canadian expertise and capacity for innovation in the promising field of cellular immunotherapy for cancer, including CAR-T therapy. The first CLIC clinical trial launched in 2019 at The Ottawa Hospital and at BC Cancer, with support from BioCanRx, BC Cancer, BC Cancer Foundation, The Ottawa Hospital Foundation, the Ontario Institute for Cancer Research, the Ottawa Regional Cancer Foundation and the Leukemia and Lymphoma Society of Canada. Core facilities and resources supporting CLIC include The Ottawa Hospital’s Biotherapeutics Manufacturing Centre, BC Cancer’s Conconi Family Immunotherapy Lab, the Ottawa Methods Centre and the Blueprint Translational Research Group. CLIC team investigators include Drs. Natasha Kekre, Harold Atkins, John Bell, Kevin Hay, Rob Holt, Brad Nelson, John Webb, Julie Nielsen, Manoj Lalu, Kednapa Thavorn, Dean Fergusson, Justin Presseau and Jen Quizi.
 
Media contact
Jenn Ganton
Director, Communications and Public Relations
Ottawa Hospital Research Institute
613-614-5253; jganton@ohri.ca

Resources for media
Access my Videos and Articles
Twitter
Facebook
Website
Copyright © 2022 FreeRange, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp